Breaking News

FCC Delays Auction of Airwaves Until Early 2016
Tweet TWEET

DGAP-News: Apricus Biosciences Announces Corporate Update Conference Call

DGAP-News: Apricus Biosciences Announces Corporate Update Conference Call

Apricus Biosciences, Inc. 

09.08.2013 13:00
---------------------------------------------------------------------------

Conference Call/Webcast to be Held Monday, August 12, 2013 at 9:00 AM ET

SAN DIEGO, 2013-08-09 13:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(www.apricusbio.com) announced today that it will hold a conference call to
discuss its recent corporate highlights on Monday, August 12, 2013 at 9:00 AM
ET. 

The call can be accessed in the U.S. by dialing (877) 407-8031 and outside of
the U.S. by dialing (201) 689-8031 and asking the conference operator for the
Apricus Bio Conference Call. The conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171412. The teleconference
replay will be available for one week by dialing in the U.S. (877) 660-6853 and
outside of the U.S. by dialing (201) 612-7415. Replay Passcode 418593 is
required for playback. The webcast replay will be available for three months. 

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros(r), for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners which include, Abbott
Canada, Takeda Pharmaceuticals International GmbH, Sandoz, and Bracco SpA.
Femprox(r), the Company's product candidate for the treatment of female sexual
interest / arousal disorder, has successfully completed a nearly 400-subject
proof-of-concept study. 

For further information on Apricus Bio, visit http://www.apricusbio.com.


         CONTACT: Apricus Bio Investor Relations:
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com
News Source: NASDAQ OMX



09.08.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Apricus Biosciences, Inc.
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         US9901429525
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------
 
Press spacebar to pause and continue. Press esc to stop.